New drug combo with standard therapy for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new combination of treatments—a targeted drug that delivers cancer-killing medicine directly to tumor cells, an immunotherapy that helps your immune system fight cancer, and standard chemoradiation—for people with advanced nasopharyngeal cancer. The goal is to see if this combination works better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have newly diagnosed nasopharyngeal cancer (cancer in the back of the nose or throat) that has not been treated yet.
- Your cancer must be at an advanced stage (stage 4, or stage 3 with spread to lymph nodes).
- You must be able to do daily activities with little or no help (ECOG score 0 or 1).
- You must have good organ function (liver, kidneys, blood counts) based on blood tests.
- You must not have other active cancers, serious infections, or uncontrolled heart, lung, or blood sugar problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a drug called MRG003 combined with another therapy that boosts the immune system to fight cancer. It aims to see if this combination can shrink tumors or slow the growth of nasopharyngeal cancer that has returned or spread.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
This trial tests a new drug called Becotatug Vedotin for people with locally advanced nasopharyngeal cancer whose tumor did not shrink enough after initial chemotherapy plus immunotherapy. If you qualify, you may receive this targeted therapy to help control the disease.
This trial tests a combination of two drugs (becotatug vedotin and an anti-PD1 immunotherapy) as maintenance treatment after initial chemotherapy for advanced nasopharyngeal cancer that has spread or returned. It's for people whose disease has not progressed after standard first-line treatment.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.